Growth Metrics

Compass Therapeutics (CMPX) Debt Ratio (2019 - 2021)

Compass Therapeutics recorded quarterly Debt Ratio of 0.11 in Q3 2021, down 30.82% quarter-over-quarter from 0.16 in Q1 2021, and down 41.82% year-over-year from 0.18 in Q3 2020.

Compass Therapeutics' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.11 for Q3 2021.

  • In Q3 2021, Debt Ratio fell 41.82% year-over-year to 0.11; the TTM figure through Sep 2021 stood at 0.11 (down 41.82% YoY), while the FY2020 annual figure was 0.18, down 44.18% from the prior year.
  • Debt Ratio came in at 0.11 for Q3 2021 at Compass Therapeutics, down from 0.16 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.32 in Q4 2019 to a low of 0.11 in Q3 2021.
  • A 3-year average of 0.19 and a median of 0.18 in 2020 frame the typical range for Debt Ratio.
  • Across the five-year window, Debt Ratio plunged 44.18% in 2020 and plunged 41.82% in 2021, its largest moves.
  • Compass Therapeutics' Debt Ratio stood at 0.32 in 2019, then tumbled by 44.18% to 0.18 in 2020, then plunged by 40.34% to 0.11 in 2021.
  • According to Business Quant data, Debt Ratio over the past three periods registered 0.11, 0.16, and 0.18 for Q3 2021, Q1 2021, and Q4 2020 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.18
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 1.41
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.05
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Compass Therapeutics 418.47 Mn 223.78 Mn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2021 0.11
Mar 31, 2021 0.16
Dec 31, 2020 0.18
Sep 30, 2020 0.18
Jun 30, 2020 0.19
Dec 31, 2019 0.32